Resources from the same session
886MO - Health-related quality of life (HRQoL) from KEYNOTE-204: A phase III, randomized, open-label study of pembrolizumab (pembro) vs brentuximab vedotin (BV) in relapsed or refractory classical Hodgkin lymphoma (R/R cHL)
Presenter: Pier Luigi Zinzani
Session: Mini Oral - Haematological malignancies
Resources:
Abstract
Slides
Webcast
887MO - Real-world treatment management of patients with advanced-stage classic Hodgkin lymphoma receiving front line therapy
Presenter: Abraham Avigdor
Session: Mini Oral - Haematological malignancies
Resources:
Abstract
Slides
Webcast
888MO - Effectiveness of brentuximab vedotin in relapsed/refractory classic Hodgkin lymphoma: A systematic review and meta-analysis
Presenter: Bastian von Tresckow
Session: Mini Oral - Haematological malignancies
Resources:
Abstract
Slides
Webcast
889MO - Long-term follow-up of patients with nodular lymphocyte predominant Hodgkin lymphoma: A report from the Spanish Lymphoma Oncology Group
Presenter: Beatriz Nunez Garcia
Session: Mini Oral - Haematological malignancies
Resources:
Abstract
Slides
Webcast
LBA37 - A blinded, randomized, parallel group, comparative investigation of a novel device (Cooral) for cryoprevention of oral mucositis
Presenter: Java Walladbegi
Session: Mini Oral - Haematological malignancies
Resources:
Abstract
Slides
Webcast
890MO - Phase I Alexander study of AUTO3, the first CD19/22 dual targeting CAR.T cell, with pembrolizumab in patients with relapsed/refractory (r/r) DLBCL
Presenter: Eleni Tholouli
Session: Mini Oral - Haematological malignancies
Resources:
Abstract
Slides
Webcast
891MO - Role of baseline PET SUVmax in predicting early progression in follicular lymphoma (FL): A single-center retrospective analysis
Presenter: Ayushi Chauhan
Session: Mini Oral - Haematological malignancies
Resources:
Abstract
Slides
Webcast
892MO - High-dose chemotherapy with autologous hematopoietic stem cell transplantation in patients with HIV-related lymphoma
Presenter: Marina Popova
Session: Mini Oral - Haematological malignancies
Resources:
Abstract
Slides
Webcast
893MO - An open-label, single-center, phase II, single-arm trial of camrelizumab combined with apatinib in patients with relapsed or refractory peripheral T-cell lymphoma
Presenter: Yan Xie
Session: Mini Oral - Haematological malignancies
Resources:
Abstract
Slides
Webcast
Invited Discussant 886MO, 887MO, 888MO and 889MO
Presenter: Stefan Balabanov
Session: Mini Oral - Haematological malignancies
Resources:
Slides
Webcast